C3d‐binding assay for the detection of complement activating HLA antibodies: A useful tool for allocation to highly sensitised recipients in the post‐ CDC era?
HLA · 2023
DOI: 10.1111/tan.15010 ↗Kurz gefasst
Fachartikel in der Zeitschrift HLA, 2023. Verfasst von Zo Ee Wong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and PathWest, Fiona Stanley Hospital, Murdoch, Western Australia, Australia. Hauptthemen laut MEDLINE: Kidney Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The CDC crossmatch test is being phased out in solid organ donor allocation, and standard luminex single antigen bead assays do not differentiate complement activating function of HLA antibodies. The current study investigated the LIFECODES C3d‐binding assay to determine if it could accurately predict actual T and B cell CDC results in a cohort of highly sensitised patients. Nineteen serum samples from different highly sensitised solid organ patients were crossmatched against cells from 62 unique donors, with 174 total T and B cell crossmatches performed. The sera also underwent SAB assay using OLI and LC platforms, and C3d‐binding assay. Complement activating ability of each unique HLA antibody specificity detected using SAB was assigned based on the actual CDC results, which was then used to determine the accuracy of the C3d‐binding assay. The C3d‐binding assay was found to be highly accurate, with sensitivity of 95%, specificity 89% and negative predictive value 97% for class I DSA and the T cell CDC crossmatch results. Furthermore, we found 100% accuracy for prediction of the complement activating function of HLA‐C antibodies. Negative predictive value of above 90% was also found for HLA class II DSA. C3d‐binding proved more accurate than virtual crossmatch alone to predict CDC results. This study confirms that the C3d‐binding assay predicts actual CDC crossmatch results accurately. In particular, the high negative predictive value of the C3d‐binding assay may be extremely useful to define HLA antibodies that do not activate complement in highly sensitised recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology and PathWest, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
- School of Biomedical Sciences, University of Western Australia, Nedlands, Western Australia, Australia.
- School of Medicine, University of Western Australia, Nedlands, Western Australia, Australia.
ORCID-Profile: Zo Ee Wong, Jonathan Downing, Dianne De Santis, Lloyd J D'Orsogna
Zitieren
APA
Wong, Z. E., Downing, J., De Santis, D., Halse, M., Bruce, S., Truong, L., Martinez, P., & D'Orsogna, L. J. (2023). C3d‐binding assay for the detection of complement activating HLA antibodies: A useful tool for allocation to highly sensitised recipients in the post‐ CDC era?. HLA. https://doi.org/10.1111/tan.15010
Vancouver
Wong ZE, Downing J, De Santis D, Halse M, Bruce S, Truong L, et al. C3d‐binding assay for the detection of complement activating HLA antibodies: A useful tool for allocation to highly sensitised recipients in the post‐ CDC era?. HLA. 2023. doi:10.1111/tan.15010
BibTeX
@article{Wong2023,
author = {Wong, Zo Ee and Downing, Jonathan and De Santis, Dianne and Halse, Megan and Bruce, Samuel and Truong, Linh and Martinez, Patricia and D'Orsogna, Lloyd J},
title = {C3d‐binding assay for the detection of complement activating HLA antibodies: A useful tool for allocation to highly sensitised recipients in the post‐ CDC era?},
journal = {HLA},
year = {2023},
doi = {10.1111/tan.15010}
}
EUVIMED